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APPENDIX SUPPLEMENTARY METHODS
Cell culture
M199 medium was supplemented with 2.5% vol/vol FBS, 10 μg/ml insulin, 0.5 μg/ml hydrocortisone, 20 ng/ml epidermal growth factor (EGF, Sigma-Aldrich), 100 ng/ml cholera toxin (Sigma-Aldrich), 0.5 μg/ml amphotericin B, 2 mM l-Glutamine (Sigma-Aldrich), 50 IU/ml penicillin and 50 μg/ml streptomycin. Modified M87 medium was composed of DMEM/F12 + Glutamax (Life Technologies) supplemented with 2% vol/vol FBS, 0.7x insulin-transferrin-selenium-x (Life Technologies), 50 IU/ml penicillin, 50 μg/ml streptomycin, 5 ng/ml EGF, 0.3 µg/ml hydrocortisone (Sigma-Aldrich), 0.5 µg/ml cholera toxin, 5 nM Triiodo-L-thyronine (T3) (Sigma-Aldrich), 0.5 nM β-estradiol (Sigma-Aldrich), 5 µM isoproterenol (Sigma-Aldrich), 50 nM ethanolamine (SigmaAldrich) and 50 nM phosphorylethanolamine (Sigma-Aldrich).
In vitro proliferation assay
Proliferation of MDA231-LM2 cells was analyzed using a Cell Titer Blue assay ( 
Migration assay
Cells were seeded onto 6-well plates and cultured to confluence. We generated approximately 800 µm wide scratches to the culture using a sterile pipette tip. 
Oncosphere formation analysis
To analyze oncosphere formation ability, cancer cells were plated onto 96-well ultra-low attachment plates (Corning) in either full oncosphere medium or HuMEC-medium without supplements at a density of 10,000 cells/ml (200 µl per well). Sphere formation was quantified by counting total number of spheres per well with the help of a Zeiss Primovert microscope. Ten wells were quantified per condition.
Generation of SUM159-LM1
Highly metastatic SUM159-LM1 cell line was generated from SUM159 breast cancer cells by in vivo selection as described in (Minn et al, 2005) . Briefly, 500,000 TGL-labeled SUM159 cells were inoculated into the lungs of NSG mice via injection into the lateral tail vein. Upon detection of bioluminescent signal in the lungs, mice were sacrificed and lungs were collected and disassociated, first mechanically using a scalpel and then enzymatically by treatment with 0.5% collagenase III (Worthington Biochemical) and 1% dispase II (Life Technologies) in PBS for 1 hour at 37°C. Then cells were washed twice with PBS, pelleted, resuspended in trypsin and incubated for 5 minutes at 37°C. Following trypsin treatment, cells were washed in PBS and plated into adhesive flasks with the appropriate cell culture medium.
Western blot
Cells were lysed with RIPA buffer supplemented with 1x HALT protease and phosphatase inhibitor cocktail and 1x EDTA (both from Thermo Scientific). Protein concentrations were determined using the BCA Protein Assay Kit (Thermo Scientific). Proteins were separated using 4-12% Criterion™ XT Bis-Tris protein gels in the Tris/Glycine/SDS system (Bio-Rad) an transferred to Trans-Blot® Turbo™ Midi PVDF membranes using the Trans-Blot® Turbo™
Transfer System (Bio-Rad). PVDF membranes were then immunoblotted with the indicated antibodies and luminescence from HRP-conjugated secondary antibodies was detected by exposing the membranes to X-ray films (Fujifilm) or using a ChemiDoc imaging system (BioRad) upon incubation with Clarity Western ECL Substrate (Bio-Rad). For the quantification of p-JNK, JNK, p-c-Jun and c-Jun relative protein levels in normal mammary cells and cancer cells from patient samples, we measured mean grey pixel density of each band and background areas using ImageJ. We then normalized background-corrected measurements to the pixel density values of the corresponding tubulin bands. Quantified protein levels were normalized to tubulin and drawn relative to protein levels in normal mammary epithelial cells (1-7HB2).
Expression of active JNK
Restriction sites in cDNA were introduced by PCR using the following primers:
XmaI-MKK7Jnk1a1-Rv: 5'-CATCCCCGGGGAGCTCGAGTCACTGCTGC-3' PCR products and the recipient lentiviral vector pLVX-Puro were digested with BstBI and XmaI in CutSmart buffer (New England Biolabs) in two steps: first, for 2 hours at 37°C and, second, for 1.5 hours at 65°C. Digestion was followed by dephosphorylation with Antarctic Phosphatase (New England Biolabs) and the digested, dephosphorylated DNA fragments were ligated using T4 DNA ligase (New England Biolabs). HEK 293T cells were used to produce lentiviral particles by co-transfecting the cells with the pLVX-Puro vectors containing the Flag-MKK7B2Jnk1a1 or Flag-MKK7B2Jnk1a1(AFP) inserts and the packaging plasmids psPAX2 and pMD2G using Lipofectamine 2000 liposomes (Invitrogen). MDA231-LM2 and SUM159-LM1 cancer cells were infected over night with supernatant containing lentiviral particles in the presence of 8 µg/ml polybrene (Sigma-Aldrich). Infected cells were selected with 2 µg/ml (MDA231-LM2) or 4 µg/ml (SUM159-LM1) puromycin (Invitrogen) for at least 5 days.
mRNA expression analysis
Whole RNA was isolated from cells using the Qiagen RNEasy Kit (Qiagen) and cDNA was generated using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Gene expression was analyzed using SYBR Green gene expression assay (Applied Biosystems) in the ViiA 7 Real-Time PCR System (Applied Biosystems). The following primer pairs were used: 
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